A Different Approach to Inhibiting the Complement System
from RARECast
The complement system, part of the immune system, has long been used as a target for interventions in certain rare disease. Apellis Pharmaceuticals is developing therapies to treat rare blood and kidney diseases, but by targeting a different part of the complement system than available therapies do today. We spoke to Cedric Francois, co-founder, president and CEO of Apellis, about the complement system, Apellis’ approach, and why he thinks this will lead to better therapies for these rare diseases.
Embed this episode
No transcript yet.
Frequently asked questions
How long is this episode of RARECast?
This episode is 18 minutes long.
When was this RARECast episode published?
This episode was published on March 6, 2019.
Can I download this RARECast episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.